Polyclonal Antibody to Ubiquitin Like Modifier Activating Enzyme 2 (UBA2)
| Code | Size | Price |
|---|
| PAG158Hu01-20ul | 20ul | £90.00 |
Quantity:
| PAG158Hu01-100ul | 100ul | £169.00 |
Quantity:
| PAG158Hu01-200ul | 200ul | £229.00 |
Quantity:
| PAG158Hu01-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SAE2; ARX; SUMO1 Activating Enzyme Subunit 2; Anthracycline-associated resistance ARX; Ubiquitin-like 1-activating enzyme E1B; SUMO-activating enzyme subunit 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Ubiquitin Like Modifier Activating Enzyme 2
Reactivity:
Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blottin:g: 0.1-2ug/mL;
Immunohistochemistry: 1-20ug/mL;
Immunocytochemistry: 1-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1-20ug/mL;
Immunocytochemistry: 1-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Ubiquitin Like Modifier Activating Enzyme 2 (UBA2) | RPG158Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||